|
||
| Gilenya News Channel |  |
|
|
|||||
|
|||||
|
|||||
| MS NEWS ARCHIVES: by week | |||||
| July 2013 | |||||
| September 2013 | |||||
| October 2013 | |||||
| June 2014 | |||||
| July 2014 | |||||
| January 2015 | |||||
| February 2015 | |||||
| March 2015 | |||||
| April 2015 | |||||
| May 2015 | |||||
| July 2015 | |||||
| March 2016 | |||||
| April 2016 | |||||
| May 2016 | |||||
| June 2016 | |||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
| HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS | |||||
 |
|||||
| |||||
| |||||
 Click to view 1280 MS Walk photos! | |||||
|
|||||
|
|||||
|
|||||
Sunday
Receptor variation influences Gilenya (fingolimod) efficacy in mouse MS models
Image Source: MAX-PLANCK-GESELLSCHAFT
Multiple sclerosis (MS) is an autoimmune disorder that results in demyelination of neurons. The FDA-approved drug fingolimod (Gilenya, FTY-720) modulates signaling by the bioactive lipid sphingosine-1-phosphate (S1P), which is linked to MS pathogenesis. Fingolimod treatment reduces relapse rates and neurologic disability in many individuals with MS; however, the drug is less effective in some patients. In this issue of JCI Insight, May Han of Stanford University and colleagues tested the hypothesis that genetic variants of the cell surface receptor that responds to S1P, S1PR1, may influence the efficacy of fingolimod.
Read more »
Labels: Study
Wednesday
Multimodal evoked potentials follow up in MS patients under Gilenya (fingolimod) therapy: STUDY
Sunday
Effect of Gilenya (fingolimod) on diffuse brain tissue damage in relapsing-remitting MS patients
Impact of a switch to Gilenya (Fingolimod) on depressive symptoms in patients with relapsing MS: An analysis from the EPOC (Evaluate Patient OutComes) trial: STUDY
Rebound Syndrome in Patients With MS After Cessation of Gilenya (Fingolimod) Treatment: STUDY
Image Source: AMSEL
Importance The appropriate sequencing of agents with strong immune system effects has become increasingly important. Transitions require careful balance between safety and protection against relapse. The cases presented herein highlight that rebound events after ceasing fingolimod treatment may happen even with short washout periods (4 weeks) and may perpetuate despite steroid treatment or the immediate use of fast-acting immune therapies, such as rituximab.
Read more »
Labels: Study
Wednesday
Gilenya (Fingolimod) Shown to Benefit Neurons as Well as Immune System
The immune system-suppressing multiple sclerosis (MS) drug fingolimod also has potentially beneficial effects on the nervous system, according to a recent study, “The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration.“ The article appeared online March 12 in an early version of the journal Experimental Neurology.
Read more »
Labels: Study
Disease-modifying treatments for MS – a review of approved medications: STUDY
The management and outcomes of Gilenya (fingolimod) first dose cardiac monitoring in UK patients with relapsing-remitting MS: STUDY
Novartis’ MS Drug Gilenya Prevents Activation of Key Immune Cells in Study: STUDY
In a recent study entitled “Myeloid cells as target of fingolimod action in multiple sclerosis,” a team of scientists investigated the impact of fingolimod (Gilenya, Novartis), an approved drug for multiple sclerosis (MS), on the reactivity of myeloid cells, a key group that comprises several immune cells that are activated in MS patients and the underlying cause of the disease. The study was published in the journal Neurology.
Read more »
Labels: Study
.jpg)
.jpg)